Alzheimer's Disease

Alzheimer's Disease (AD)

An estimated 6.7 million Americans age 65 and older are living with Alzheimer's in 2023¹.

With deaths more than doubled between 2000 and 2019, the total estimated Alzheimer's healthcare costs for treatment in 2020 is estimated at $305 billion, with an increase to more than $1 trillion as the population ages².

Analysis shows that early diagnosis and disease management with pharmacologic and nonpharmacologic measures would lead to cost savings and earlier diagnosis.

Sources: 1) https://www.alz.org/alzheimers-dementia/facts-figures

OM1 Alzheimer's Disease Specialty Dataset

Fully utilize deep, clinical RWD to more efficiently design and conduct clinical trials such as uncovering subtypes to: determine which groups the protocol should be designed to enroll.
Measure key safety outcomes of interest and support regulatory requirements such as: comparing the real-world safety profiles for patients on first- and second-generation antiepileptic drugs.

*Counts complete through Q2 2024

16,000+*

Alzheimer’s patients with deep clinical data longitudinally followed by specialists

7 years

Mean followup per patient

97%

With linked EMR & claims (medical or pharmacy)